FATE - Fate Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue4,7404,1064,4022,431
Cost of Revenue56,02434,35826,45219,861
Gross Profit-51,284-30,252-22,050-17,430
Operating Expenses
Research Development----
Selling General and Administrative15,80811,8739,91310,352
Non Recurring----
Others----
Total Operating Expenses71,83246,23136,36530,213
Operating Income or Loss-67,092-42,125-31,963-27,782
Income from Continuing Operations
Total Other Income/Expenses Net494-827-1,499-2,210
Earnings Before Interest and Taxes-67,092-42,125-31,963-27,782
Interest Expense-1,696-1,268-1,637-2,220
Income Before Tax-66,598-42,952-33,462-29,992
Income Tax Expense----
Minority Interest----
Net Income From Continuing Ops-66,598-42,952-33,462-29,992
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-66,598-42,952-33,462-29,992
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-66,598-42,952-33,462-29,992